neuroendocrine tumor

February 16, 2023

Targeted therapy for neuroendocrine tumors

Cancer therapies that target VEGF receptor appear safe and effective for patients with pancreatic and non-pancreatic neuroendocrine tumors, meta-analysis of phase 2/3 clinical trials demonstrates.

By Kelsey Pinckard
January 19, 2022

Clinical score can guide PRRT therapy decisions for neuroendocrine tumors

A clinical score system developed by researchers at Vanderbilt-Ingram Cancer Center (VICC) has been validated that can guide peptide receptor radionuclide therapy treatment decisions.

By Tom Wilemon
November 2, 2021

Shifts in neuroendocrine cancer clinical trial design

Clinical trials that focus on specific types of neuroendocrine neoplasms — heterogeneous tumors that can occur anywhere in the body — will be more likely to enhance drug development for these tumors, Vanderbilt physicians assert.

By Leigh MacMillan
March 5, 2020

Das lands support for neuroendocrine tumor research

Satya Das, MD, has been awarded a $300,000 grant for a two-year period by the Neuroendocrine Tumor Research Foundation.

By Tom Wilemon
January 6, 2017

Midgut neuroendocrine tumor prognosis

Vanderbilt investigators recommend that the presence of tumor deposits in the abdomen be included when staging midgut neuroendocrine tumors.

By Leigh MacMillan
June 24, 2016

Superior scan for tumors

Imaging with a compound that binds to neuroendocrine cells is a safer and more effective way to detect rare neuroendocrine tumors.

By Bill Snyder
October 21, 2015

Biomarker for intestinal tumors

A new marker could be useful for diagnosing and treating neuroendocrine tumors of the small intestines.
By Leigh MacMillan
April 24, 2014

VICC debuts novel neuroendocrine tumor treatment

A retired elementary school principal has become the first patient at Vanderbilt-Ingram Cancer Center to receive an investigational cancer therapy for the treatment of his neuroendocrine tumor.
By VUMC News and Communications